Name: Levonorgestrel
Brand: Selleck Chemicals
SKU: S1727
Rating: 5 (5 reviews)

Ga naar

Kwaliteitscontrole (Quality Control)

Batch: Zuiverheid: 99.95%

99.95

Gerelateerde doelwitten	Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR PGES
Overige Estrogen/progestogen Receptor Inhibitoren	Elacestrant (RAD1901) Dihydrochloride Vepdegestrant (ARV-471) MPP dihydrochloride Kaempferol Cholesterol PHTPP G15 Licochalcone A Endoxifen HCl Pregnenolone

Chemische informatie, Opslag en Stabiliteit (Chemical Information, Storage & Stability)

Moleculair gewicht	312.45	Formule	C₂₁H₂₈O₂	Opslag (Vanaf de ontvangstdatum)	3 jaar-20°Cpoeder
CAS-nr.	797-63-7	SDF downloaden		Opslag van stamoplossingen	1 jaar-80°Cin oplosmiddel 1 maand-20°Cin oplosmiddel
Synoniemen	D-Norgestrel			Smiles	CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34

Oplosbaarheid (Solubility)

In vitro
Batch:

DMSO : 62 mg/mL (198.43 mM)
(Met vocht verontreinigde DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molariteitscalculator

Massa	Concentratie	Volume	Moleculair gewicht
=	×	×

Verdunningscalculator Moleculair gewicht calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formuleringscalculator (Heldere oplossing)

Stap 1: Voer de onderstaande informatie in (Aanbevolen: Een extra dier voor het geval van verlies tijdens het experiment)

Dosering: mg/kg Gemiddeld gewicht van dieren: g Doseervolume per dier:μL Aantal dieren:

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in het gedeelte Oplosbaarheid.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-mastervloeistof: mg geneesmiddel vooraf opgelost in μL DMSO ( Concentratie mastervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de partij geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO mastervloeistof, voeg vervolgens toeμL PEG300, mengen en helder maken, voeg vervolgens toeμL Tween 80, mengen en helder maken, voeg vervolgens toe μL ddH₂O, mengen en helder maken.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO mastervloeistof, voeg vervolgens toe μL Maïsolie, mengen en helder maken.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysische methoden zoals vortexen, echografie of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme (Mechanism of Action)

Targets/IC₅₀/Ki	Progesterone receptor
In vitro	Levonorgestrel suppresses the stimulation of progesterone secretion induced by oLH, dibutyryl-cAMP and Pregnenolone in rats luteal cells. This compound also inhibits constrictions evoked by either a high potassium (K(+)) solution or phorbol myristate acetate (PMA) in the absence and presence of extracellular calcium (Ca(2+)). It depresses contractions evoked by Ca(2+) and reduces (45)Ca(2+) influx in depolarized veins. The chemical increases levels of cyclic AMP and inhibits PMA-induced activation of protein kinase C in veins. It causes endothelium-independent relaxations of jugular veins via inhibition of Ca(2+) entry and of protein kinase Cactivation. Its inhibition of both estrogen-induced pituitary weight increment and hyperprolactinemia is reduced by mifepristone, whereas Flutamide is unable to block this compound's effects
In vivo	Levonorgestrel down-regulates the mRNA expression of follicle-stimulating hormone receptor (FSHR), luteinizing hormone receptor (LHR), estrogen receptor (ER) β and progesterone receptor (PR) in the ovary, and ERα and PR in the uterus of Mongolian gerbils. This compound causes a significant upregulation of the mRNA expression of the gene encoding luteinising hormone β-subunit (lhβ) and the suppression of the mRNA expression of the gene encoding follicle-stimulating hormone β-subunit (fshβ) in the pituitary of both male and female roach. It disrupts the reproductive system of pubertalroach by affecting the pituitary gonadotropin expression and the sex steroid levels in pubertal roach (Rutilus rutilus).
Referenties	[1] https://pubmed.ncbi.nlm.nih.gov/8049144/ [2] https://pubmed.ncbi.nlm.nih.gov/10952682/ [3] https://pubmed.ncbi.nlm.nih.gov/1854838/ [4] https://pubmed.ncbi.nlm.nih.gov/21791876/ [5] https://pubmed.ncbi.nlm.nih.gov/24893273/

Informatie klinische proef (Clinical Trial Information)

(gegevens van https://clinicaltrials.gov, bijgewerkt op 2026-03-04)

NCT-nummer	Rekrutering	Aandoeningen	Sponsor/Medewerkers	Startdatum	Fasen
NCT07449299	NOT_YET_RECRUITING	Emergency Contraception; Contraception; COX-2 Inhibitor	University of Utah	2027-03	PHASE3
NCT07462663	NOT_YET_RECRUITING	Endometrial Cancer; Endometrial Cancer Stage I; Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I; Atypical Endometrial Hyperplasia; Endometrial Intraepithelial Neoplasia; Obesity & Overweight; BMI>40; Obesity; Obesity Grade III	Hospital Universitari de Bellvitge	2027-01	PHASE4
NCT07734155	NOT_YET_RECRUITING	Contraceptive Usage	Chemo Research	2026-12	PHASE3
NCT07627958	NOT_YET_RECRUITING	Vaginal Microbial Diversity	Seattle Children's Hospital	2026-07
NCT07781150	NOT_YET_RECRUITING	Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer	Tongji Hospital	2026-11-01	PHASE2
NCT07536763	NOT_YET_RECRUITING	Contraception	Dr. Hang Wun Raymond Li	2026-07	PHASE3

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Levonorgestrel Estrogen/progestogen Receptor Agonist

Moleculair gewicht: 312.45